The Best Group Nutrition Programs for Weight Loss: A Comprehensive Guide
Everyone has a different idea or method for losing weight. These leaders in nutrition offer guidance on finding the right fit.
presented by
Knownwell Opens 6 New Clinics in Chicago
Obesity care company knownwell expanded into six new clinic locations across greater Chicago. The company now operates eight clinics, as it has existing locations in Boston and Dallas. Knownwell also provides virtual care services to patients across New England, Texas and Illinois.
What Are Healthcare Organizations Getting Wrong about Email Security?
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
Metabolic Meds Startup Verdiva Launches With $411M and a Weekly Oral GLP-1 Drug
Verdiva Bio’s once-a-week oral GLP-1 drug is ready for Phase 2 testing. The drug, made with a proprietary technology that enables oral dosing, was licensed from Sciwind Biosciences.
Biopharma in 2025: Outlook for Obesity Meds, Drug Prices, Regulation & More
Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things to look for include more widespread adoption of artificial intelligence technologies and the IPO market’s return to normal levels.
A New Era in OSA: Bridging the Gap with Novel Treatment Solutions
We must think beyond one-size-fits-all solutions and embrace the diversity of obstructive sleep apnea. This means continuing to innovate, collaborating across sectors, and keeping patients at the center of every decision.
The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender
Corxel Pharmaceuticals has acquired an oral small molecule GLP-1 agonist with potential applications in obesity and diabetes. The Phase 2-ready pill could compete with oral metabolic meds in development by companies such as Roche, AstraZeneca, and Structure Therapeutics.
presented by
The Top 5 Home Care Franchise Opportunities in the U.S.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
Video: Battle of the Bulge – Wegovy vs. Zepbound
The GLP-1 battle heats up with new preliminary data from Eli Lilly showing that patients using its weight loss drug Zepbound lost more weight on average in 72 weeks than those on Novo Nordisk's Wegovy.
Weight Loss With Amgen Drug in Line With Eli Lilly Med, But Dosing Could Be Differentiator
Amgen’s experimental obesity drug, MariTide, led to an average 20% reduction in weight in a Phase 2 clinical trial. While investors hoped for greater weight loss, some analysts say less burdensome monthly dosing of MariTide could make it competitive against weekly injectable weight drugs Zepbound and Wegovy.
A Recipe for Better Obesity Care: Integrating GLP-1s with Food as Medicine
Nutrition isn’t a supplement — it’s foundational to metabolic health. It’s time we integrate more ‘Food as Medicine’ initiatives alongside the GLP-1 therapies that are gaining traction.
Exercise Benefit in a Pill: BioAge Labs Goes Public, Raising More Than $200M for Clinical Trials
BioAge Labs’ lead drug candidate, azelaprag, is in Phase 2 testing in combination with Eli Lilly’s weight management medication Zepbound. The biotech’s oral drug activates a receptor it says can mimic certain biological effects of exercise.
presented by
A Path to Healing: Discovering Arizona’s PTSD Treatment Centers
Explore top PTSD treatment centers in Arizona, offering personalized care, holistic therapies and expert support to help individuals heal and reclaim their lives.
Knownwell Acquires Competitor to Expand Access to Comprehensive Obesity Care
Knownwell acquired one of its competitors, just six months after announcing its $20 million Series A funding round. The startup, which provides hybrid primary care and metabolic health treatment, bought Alfie Health, an online obesity management clinic with an AI platform that generates personalized recommendations for weight management.
Hims & Hers Offers Access to GLP-1s Starting At $199 A Month
Hims & Hers is now providing access to compounded GLP-1s. Patients also receive unlimited medical consultations with a licensed provider.
MedCity Pivot Podcast: A Conversation with Lumen CEO Daniel Tal Mor
In this episode, the CEO of Lumen talks about the sleek consumer device and why he is at a b-to-b healthcare conference.
Lose Fat, Not Muscle: Next Test for Lilly’s Zepbound Pairs It With BioAge Drug
In preclinical testing, combining BioAge Labs’ experimental drug with Eli Lilly weight drug Zepbound led to greater weight loss compared with Zepbound alone. Now the company plans to run a Phase 2 study to see if it can replicate those results in humans.
Metabolic Disorder-Focused Fractyl Health ‘GUTS’ Out a $110 Million IPO
Fractyl Health will use the IPO proceeds for pivotal testing of a medical device and surgical procedure intended to address root causes of diabetes and obesity. The Fractyl pipeline also includes a gene therapy for these conditions.